Bioniz Therapeutics is slated to start a Phase I trial for one of its cytokine inhibitors in partnership with the National Institutes of Health (NIH). Now, it’s nabbed a $13 million cash infusion in a Series A financing to advance that and other work.
The round was co-led by Takeda Ventures and Dr. David Pyott, who was previously chairman and CEO of Allergan. Cota Capital and Joe Kiani, the chairman and CEO of patient monitoring company Masimo ($MASI), also participated.
Click here to read the full article on Fierce Biotech.